Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study
- 23 February 2011
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 25 (12), 1402-1408
- https://doi.org/10.1111/j.1468-3083.2011.03984.x
Abstract
Background Palmoplantar psoriasis is a difficult to treat variant of plaque psoriasis. Objective To study the safety and efficacy of infliximab in non‐pustular palmoplantar psoriasis. Methods Patients with non‐pustular palmoplantar psoriasis affecting at least 10% of their palms and soles and with a modified palmoplantar psoriasis area and severity index (m‐PPPASI) of at least eight were recruited. Patients were randomized (1:1) to receive infliximab 5 mg/kg or placebo at weeks 0, 2 and 6. Patients initially randomized to placebo received infliximab at weeks 14, 16 and 20 whereas patients randomized to infliximab received additional infliximab infusions every 8 weeks until week 22. Results Twenty four (24) patients were randomized in this study. At week 14, 33.3% and 66.7% of patients treated with infliximab achieved m‐PPPASI 75 and m‐PPPASI 50 respectively compared to 8.3% for both m‐PPPASI 75 (P = 0.317) and m‐PPPASI 50 (P = 0.009) for patients randomized to placebo. A reduction of 50.3% in the mean surface area of palms and soles affected with psoriasis was seen at week 14 in patients randomized to infliximab as compared to an increase of 14.9% in patients randomized to placebo (P = 0.009). Conclusions This pilot study did not reach its primary endpoint of m‐PPPASI 75 at week 14. However, infliximab was observed to be more efficacious than placebo in improving PPSA and with respect to the percentage of patients reaching m‐PPPASI 50 at week 14. Larger and longer term studies are needed for severe patients to better assess the efficacy of infliximab in palmoplantar psoriasis.Keywords
This publication has 10 references indexed in Scilit:
- Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment toolJournal of the American Academy of Dermatology, 2009
- Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanerceptClinical Rheumatology, 2009
- Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisisClinical and Experimental Dermatology, 2009
- Efalizumab for severe palmo‐plantar psoriasis: an open‐label pilot trial in five patientsJournal of the European Academy of Dermatology and Venereology, 2009
- Tumor necrosis factor inhibitor–induced pustular psoriasis?Journal of the American Academy of Dermatology, 2007
- Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic ConditionsArchives of Dermatology, 2007
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJournal of the American Academy of Dermatology, 2007
- Hepatitis: a rare, but important, complication of infliximab therapy for psoriasisClinical and Experimental Dermatology, 2006
- Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?British Journal of Dermatology, 2005
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialThe Lancet, 2005